Engelhard, Herbert H.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA

Glioma Diagnosis and TreatmentMathematical Biology Tumor Growth

Cited by 1,259

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer

Glioma Diagnosis and TreatmentElectromagnetic Fields and Biological Effects

Cited by 862

Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)

Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L., Annenelie Bota, D., Rudnick, J., Love Sumrall, A., Zhu, J.-J., et al. (2014) · Seminars in Oncology

Glioma Diagnosis and TreatmentCancer survivorship and care

Cited by 152

Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues

Naseri Kouzehgarani, G., Feldsien, T., Engelhard, H. H., Mirakhur, K. K., Phipps, C., Nimmrich, V., Clausznitzer, D., & Lefebvre, D. R. (2021) · Advanced Drug Delivery Reviews

Cerebrospinal fluid and hydrocephalusBarrier Structure and Function Studies

Cited by 95